Two Healthcare workers Experienced Harsh Allergic Reactions to the New Pfizer Vaccine.
Firstly I want to clarify this event. Yesterday the UK was the first country to start vaccinating its citizens with the new Pfizer vaccine. Healthcare workers and the elderly (80+) were the first to receive the new treatment. As of right now, we are unsure of the symptoms they show but we do know that each of them had a history of intense anaphylactoid reactions long before receiving the Pfizer vaccine. This type of reaction can be serious and life-threatening but they both were prepared and were carrying adrenaline autoinjectors, to calm the reaction. The good news is, both have recovered.
Resuscitation equipment on hand
The UK has stated that people should only be receiving the vaccine in locations that have resuscitation equipment on hand. But let’s look at this more closely. Here in the US about 1 out of every 1.4 million people receiving a vaccination will have an allergic reaction to it. So the chance of having a reaction is very very small. Keep in mind though that of the 42,000 people who participated in the clinical trials, none of them had a history of severe allergic reactions. So I do agree that if you are someone who has suffered severe life-threatening allergic reactions before in the past, you may not want to receive the vaccine until we know more.
FDA Pfizer Hearing
It looks pretty clear that the FDA will approve the Pfizer vaccine as 3 countries have already (Canada, UK, and Bahrain). Especially because they recently released a document stating the Pfizer was highly effective and very safe. The meeting tomorrow, which consists of independent medical experts, will talk about the pros and cons of the new vaccine. After that, they will have a vote which will determine whether or not they advise the FDA to approve the new vaccine. That does not mean the FDA needs to accept.
Common Side Effects
Side Effects have been seen more commonly in patients younger than 55 and include pain, redness, or swelling where the shot was given after the first shot and headaches, muscle pain, and short-term fatigue after the second. Those usually followed the second shot. With fatigue occurring 59% and headache occurring 52% in participants aged 55 and younger.